Referanslar

• Alhayani, T., Philpott, C. D., Liao, S., Gentene, A. J., & Mueller, E. W. (2024). Comparison of doxycycline or minocycline to sulfamethoxazole-trimethoprim for treatment of Stenotrophomonas maltophilia pneumonia. Annals of Pharma-cotherapy, 58(1), 21-27. google scholar
• Andelkovic, M. V., Jankovic, S. M., Kostic, M. J., Zivkovic Zaric, R. S., Opancina, V. D., Zivic, M. Z., ... & Pejcic, A. V. (2019). An-timicrobial treatment of Stenotrophomonas maltophilia invasive infections: systematic review. Journal of Chemotherapy, 31(6), 297-306. google scholar
• Banar, M., Sattari-Maraji, A., Bayatinejad, G., Ebrahimi, E., Jabal-ameli, L., Beigverdi R, & Jabalameli, F. (2023). Global prevalence and antibiotic resistance in clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis. Frontiers in Medicine, 10, 1163439. google scholar
• Biagi, M., Lamm, D., Meyer, K., Vialichka, A., Jurkovic, M., Patel S, & Wenzler, E. (2020b). Activity of aztreonam in combination with avibactam, clavulanate, relebactam, and vaborbactam against multidrug-resistant Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotheraphy 64(12), e00297-20. https://doi.org/10. 1128/AAC.00297-20 google scholar
• Biagi, M., Tan, X., Wu, T., Jurkovic, M., Vialichka, A., Meyer K. & Wenzler, E. (2020a). Activity of potential alternative treatment agents for Stenotrophomonas maltophilia isolates nonsusceptible to levofloxacin and/or trimethoprim-sulfamethoxazole. Journal of Clinical Microbiology, 58(2), e01603-19. https://doi.org/10.1128/ JCM.01603-19 google scholar
• Brooke, J. S. (2021). Advances in the microbiology of Stenotrophomonas maltophilia. Clinical Microbiology Reviews, 34(3), e00030-19. https://doi.org/10.1128/CMR.00030- 19 google scholar
• Cai, B., Tillotson, G., Benjumea, D., Callahan, P., & Echols, R. (2020). The burden of bloodstream infections due to Stenotrophomonas maltophilia in the United States: a large, retrospective database study. In Open Forum on Infectious Diseases (Vol. 7, No. 5, p. ofaa141). US: Oxford University Press. google scholar
• CLSI (Clinical and Laboratory Standards Institute). (2006). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—seventh edition: M07. Wayne, PA, USA: CLSI google scholar
• CLSI (Clinical and Laboratory Standards Institute). (2023). Perfor-mance standards for antimicrobial susceptibility testing. 33rd ed. CLSI M100. Wayne, PA, USA: CLSI. google scholar
• Cornely, O. A., Cisneros, J. M., Torre-Cisneros, J., Rodriguez-Hernandez, M. J., Tallon-Aguilar, L., Calbo, E., ... & Luckey, A. (2020). Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hos-pitalized adults: results from the REJUVENATE study. Journal of Antimicrobial Chemotherapy, 75(3), 618-627. google scholar
• Dadashi, M., Hajikhani, B., Nazarinejad, N., Noorisepehr, N., Yazdani, S., Hashemi, A., ... & Fatemeh, S. (2023). Global prevalence and distribution of antibiotic resistance among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis. Journal of Global Antimicrobial Resistance 34, 253-267. https://doi.org/10.1016/j.jgar.2023.02.018 google scholar
• de Almeida Torres, N., Junior, R. M., Lopes, L. F. B., Zeigler, R., & Uip, D. E. (2023). Synergistic combination of aztreonam and ceftazidime/avibactam against resistant Stenotrophomonas mal-tophilia on pancreatitis. The Journal of Infection in Developing Countries, 17(06), 881-885. google scholar
• Eliopoulos, G. & Moellering Jr., R.C. (1996). Antimicrobial Combi-nations. In: Lorian, V., (Ed.), Antibiotics in Laboratory Medicine (pp. 330-396), Baltimore, USA, The Williams & Wilkins Co. google scholar
• Emeraud, C., Escaut, L., Boucly, A., Fortineau, N., Bonnin, R. A., Naas, T., & Dortet, L. (2019). Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by metallo-^-lactamase-producing Gram-negative bacteria. Antimi-crobial Agents and Chemotherapy, 63(5), e00010-19. google scholar
• EUCAST (The European Committee on Antimicrobial Susceptibility Testing). (2024a). Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, 2024. Retrieved from https: //www.eucast.org. google scholar
• EUCAST (The European Committee on Antimicrobial Suscepti-bility Testing). (2024b). Breakpoints for aztreonam-avibactam May 2024. Retrieved from https://www.eucast.org/clinical_ breakpoints google scholar
• Gil-Gil, T., Martmez, J. L., & Blanco, P. (2020). Mechanisms of an-timicrobial resistance in Stenotrophomonas maltophilia: a review of current knowledge. Expert Review of Anti-infective Therapy, 18(4), 335-347. google scholar
• Gülmez, D., Cakar, A., Şener, B., Hasçelik, G., & Karakaya, J. (2010). Comparison of different antimicrobial susceptibility testing meth-ods for Stenotrophomonas maltophilia and results of synergy test-ing. Journal of Infection and Chemotherapy, 16(5), 322-328. google scholar
• Hafiz, T. A., Aldawood, E., Albloshi, A., Alghamdi, S. S., Mubaraki, M. A., Alyami, A. S., & Aldriwesh, M. G. (2022). Stenotrophomonas maltophilia epidemiology, resistance charac-teristics, and clinical outcomes: understanding of the recent three years’ trends. Microorganisms, 10(12), 2506. google scholar
• Karamanlıoğlu, D., & Dizbay, M. (2019). In vitro combination of tige-cycline with other antibiotics in Stenotrophomonas maltophilia isolates. Turkish Journal of Medical Sciences, 49(2), 683-686. google scholar
• Lin, Q., Zou, H., Chen, X., Wu, M., Ma, D., Yu, H., ... & Huang, S. (2021). Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro. BMC Microbiology, 21, 1-6. google scholar
• Liu, J., Xiang, Y., & Zhang, Y. (2024). Stenotrophomonas maltophilia: An urgent threat with increasing antibiotic resistance. Current Microbiology, 81(1), 6. google scholar
• Mojica, M. F., Bonomo, R. A., & Van Duin, D. (2023). Treatment approaches for severe Stenotrophomonas maltophilia infections. Current Opinion in Infectious Diseases, 36(6), 572-584. google scholar
• Mojica, M. F., Humphries, R., Lipuma, J. J., Mathers, A. J., Rao, G. G., Shelburne, S. A., ... & Bonomo, R. A. (2022). Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC-Antimicrobial Resistance, 4(3), dlac040. google scholar
• Mojica, M. F., Papp-Wallace, K. M., Taracila, M. A., Barnes, M. D., Rutter, J. D., Jacobs, M. R., ... & Bonomo, R. A. (2017). Avibactam restores the susceptibility of clinical isolates of Stenotrophomonas maltophilia to aztreonam. Antimicrobial Agents and Chemother-apy, 61(10), e00777-17. https://doi.org/10.1128/aac.00777-17 google scholar
• Odds, F.C. (2003). Synergy, antagonism, and what the chequerboard puts between them. Journal of Antimicrobial Chemotherapy, 52, 1. https://dx.doi.org/10.1093/jac/dkg301 google scholar
• Ranieri, E. M., Denicolo, S., Stolfa, S., Dalfino, L., Bavaro, D. F., Sara-cino, A., ... & Mosca, A. (2023). Looking for Stenotrophomonas maltophilia treatment: in vitro activity of ceftazidime/avibactam alone and in combination with aztreonam. Journal of Chemother-apy, 35(7), 610-613. google scholar
• Rizvi, M., Ahmed, J., Khan, F., Shukla, I., & Malik, A. (2013). As-sessment of combination therapy by time kill curve analysis and chequerboard assay for treatment of multi-drug resistant Pseu-domonas aeruginosa isolates. Journal of Global Antimicrobial Resistance, 1(2), 103-108. google scholar
• Roemhild, R., Bollenbach, T., & Andersson, D. I. (2022). The physiol-ogy and genetics of bacterial responses to antibiotic combinations. Nature Reviews Microbiology, 20(8), 478-490. google scholar
• Rossolini, G. M., Arhin, F. F., & Kantecki, M. (2024). In vitro ac-tivity of aztreonam-avibactam and comparators against Metallo-P-Lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016-2020. Journal of Global Antimicro-bial Resistance, 36, 123-131. google scholar
• Sader, H. S., Carvalhaes, C. G., Arends, S. R., Castanheira, M., & Mendes, R. E. (2021). Aztreonam/avibactam activity against clin-ical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. Journal of Antimicrobial Chemotherapy, 76(3), 659-666. google scholar
• Sader, H. S., Castanheira, M., Kimbrough, J. H., Kantro, V., & Mendes, R. E. (2023). Aztreonam/avibactam activity against a large collec-tion of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21). JAC-Antimicrobial Resistance, 5(2), dlad032. google scholar
• Sader, H. S., Duncan, L. R., Arends, S. R., Carvalhaes, C. G., & Castan-heira, M. (2020). Antimicrobial activity of aztreonam-avibactam and comparator agents when tested against a large collection of contemporary Stenotrophomonas maltophilia isolates from med-ical centers worldwide. Antimicrobial Agents and Chemotherapy, 64(11), e01433-20. https://doi.org/10.1128/aac.01433-20 google scholar
• Singh, R., Kim, A., Tanudra, M. A., Harris, J. J., McLaughlin, google scholar
• R. E., Patey, S., ... & Eakin, A. E. (2015). Pharmacokinet-ics/pharmacodynamics of a p-lactam and p-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. Journal of Antimicrobial Chemotherapy, 70(9), 2618-2626. google scholar
• Su, B. A., Chen, C. C., Chen, H. J., Lai, H. Y., Tsai, C. H., Lai, C. C., ... & Chao, C. M. (2023). In vitro activities of antimicrobial combi-nations against planktonic and biofilm forms of Stenotrophomonas maltophilia. Frontiers in Microbiology, 14, 1186669. google scholar
• Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023). Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clinical Infectious Diseases, ciad428. google scholar
• Tyers, M., & Wright, G. D. (2019). Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nature Reviews Microbiology, 17(3), 141-155 google scholar
• U.S. Food and Drug Administration. 2023. https://www.fda.gov/drugs/ development-resources/tigecycline-injection-products. Accessed 21 September 2024.Visalli, M. A., Jacobs, M. R., & Appelbaum, P. C. (1998). Activities of three quinolones, alone and in com-bination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy, 42(8), 2002-2005. google scholar
• Wang,C.H.,Yu,C.M.,Hsu,S.T.,&Wu,R.X. (2020). Levofloxacin-resistant Stenotrophomonas maltophilia: risk factors and antibi-otic susceptibility patterns in hospitalized patients. Journal of Hospital Infection, 104(1), 46-52. google scholar
• White, R. L., Burgess, D. S., Manduru, M., & Bosso, J. A. (1996). Comparison of three different in vitro methods of detecting syn-ergy: time-kill, checkerboard, and E test. Antimicrobial Agents and Chemotherapy, 40(8), 1914-1918. google scholar
• Zhao, J., Huang, Y., Li, J., Zhang, B., Dong, Z., & Wang, D. (2022). In vitro antibacterial activity and resistance prevention of an-timicrobial combinations for dihydropteroate synthase-carrying Stenotrophomonas maltophilia. Infection and Drug Resistance, 15, 3039-3046. google scholar
• Zhao, J., Liu, Y., Liu, Y., Wang, D., Ni, W., Wang, R., ... & Zhang, B. (2018). Frequency and genetic determinants of tigecycline re-sistance in clinically isolated Stenotrophomonas maltophilia in Beijing, China. Frontiers in Microbiology, 9, 549. google scholar
• Zusman, O., Avni, T., Leibovici, L., Adler, A., Friberg, L., Ster-giopoulou, T., ... & Paul, M. (2013). Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. An-timicrobial Agents and Chemotherapy, 57(10), 5104-5111. google scholar

Atıflar